mpadvisors

pharma expert strategic advisor merger and acquisitions investment banker angel investor valuations drug in licensing drug out-license due diligence global pharma consultants deal maker pharmal consultants private equity venture capital angel investors bio-similar landscape product and portfolio divestment para iv opportunities valuation merger and acquisition opportunity otc fund raising in-licensing and out licensing product selection portfolio prioritization pharma consulting eli lilly pfizer global pharmaceutical & biotechnology outlook 2014 novo nordisk outlook 2014 glaxosmithkline novartis roche bristol-myers squibb astrazeneca merck prostate cancer actemra myrbetriq dainnipon daiichi sankyo nhi price cut kadcyla biosimilar perjeta isavuconazole japan generic opportunity xtandi ranbaxy edoxaban mpdl3280a breast cancer astellas dainnipon sumitomo chugai prograf cadila healthcare dr. reddy's ipca shilpa medicare biocon sun pharma shahsun pharma natco lupin wockhardt cipla ambi glpg pharmacyclics ambit bioscience morphosys basilea isis pharma incyte endocyte basl ablx enanata ecyt cemp onconova ablynx enta symbio galapagos cempra japan generic presence in global market japan generics pharmaceutical & biotech industry expert post excl. competition settlement innovator litigation outcome patent reissue ftf vs innovator para iv plus non ftf vs innovator citizen\'s petition withdrawal